Background
This study explored the correlation of the junctional zone, depth of myometrial invasion (DMI), and their combination (COJD) with symptom recurrence after ultrasound-guided high-intensity focused ultrasound ablation surgery (FUAS) in patients diagnosed with intrinsic adenomyosis.
Methods
A total of 326 patients undergoing FUAS between June 2017 and March 2024 were enrolled in this retrospective analysis. Symptom recurrence was defined as the return of menorrhagia or dysmenorrhea after ≥ 3 months of relief. Risk factors for recurrence were identified by logistic regression and Cox proportional hazards models. The receiver operating characteristic (ROC) analysis was conducted to determine the optimal cutoffs for maximal junctional zone thickness (JZmax) and DMI, which were utilized for constructing the COJD score.
Results
Symptom recurrence was observed in 58 patients (17.8%). Multivariate logistic regression identified JZmax as an independent predictor of recurrence (OR = 1.060, 95% CI: 1.026– 1.095, P < 0.001). The optimal cutoffs were 23.1 mm for JZmax and 51.4 mm for DMI. Besides, COJD was significantly related to recurrence in Cox regression (HR = 6.004, 95% CI: 1.125– 32.054, P = 0.036). Median recurrence-free survival reduced progressively with the increasing COJD score: 53.0 months for COJD = 0, 45.8 months for COJD = 1, and 38.7 months for COJD = 2 (P = 0.046).
Conclusion
The COJD score, combining JZmax with DMI, was an independent predictor of symptom recurrence after FUAS, with a score of two identifying patients at the highest risk of early recurrence.
Plain Language Summary: The combination of JZmax with DMI may predict adenomyotic symptom recurrence following FUAS. The COJD score was an independent predictor, with a score of 2 identifying patients at the highest risk for early recurrence.
Keywords
JZmax, DMI, COJD, intrinsic adenomyosis, symptom recurrence, focused ultrasound ablation surgery
Key Points
- COJD score combining JZmax with DMI predicted recurrence after FUAS.
- COJD = 2 was correlated with a 6-fold increased recurrence risk (HR = 6.004).
COJD = 2 identified patients at the highest risk of early recurrence.
Introduction
Adenomyosis refers to a common gynecological disorder characterized by the presence of ectopic endometrial tissue within the myometrium, usually presenting with dysmenorrhea and menorrhagia.1,2 Although hysterectomy remains the definitive treatment, it is not appropriate for women wishing to preserve fertility.3,4 Ultrasound-guided high-intensity focused ultrasound ablation surgery (FUAS) has emerged as a non-invasive alternative with favorable efficacy and safety.5,6 However, symptom recurrence is a clinically significant concern, typically occurs and typically occurs within 12 to 24 months post-treatment,7,8 underscoring the need for reliable prognostic markers.
The junctional zone (JZ), which refers to the innermost myometrial layer, has an essential effect on the adenomyosis pathogenic mechanism.9 Maximal junctional zone thickness (JZmax) has been the commonly used criterion for diagnosis, which is related to outcomes post-treatment like uterine artery embolization.10,11 However, its function in predicting recurrence post-FUAS remains largely unexplored.
In addition to JZmax, the depth of myometrial invasion (DMI), which refers to the greatest distance between the endometrial–myometrial interface and the deepest level of adenomyosis, is an important anatomical factor indicating disease burden.12 Beyond JZ alterations, the depth of myometrial invasion (DMI)—defined as the maximal distance from the endometrial–myometrial interface to the deepest extent of the adenomyotic lesion—serves as a key anatomical indicator of disease burden,13,14 can quantify the disease-related anatomical invasiveness.15 Consequently, integrating them in the composite score (COJD) assists in capturing more data on disease severity and providing higher prediction accuracy than a single parameter.
Given the high prevalence and recurrence rates of adenomyosis, and the varying success rates of FUAS reported globally, there is a pressing need to identify robust preoperative predictors. Therefore, the present work focused on evaluating the relationship between preoperative JZmax, DMI, as well as the combination (COJD) and symptom recurrence among intrinsic adenomyosis patients who underwent FUAS, determining the best cutoffs to facilitate risk stratification, and assessing whether COJD can be used to predict the recurrence timing.
Methods
Patients
This retrospective cohort study included 359 symptomatic adenomyosis patients treated at the Affiliated Nanchong Central Hospital of North Sichuan Medical College between June 2017 and June 2024. The study was approved by the hospital’s Ethics Committee (Approval No. 2021/104). After applying inclusion and exclusion criteria, 326 patients with complete clinical and follow-up data were included.
The inclusion criteria were: (a) patients with presence of dysmenorrhea or menorrhagia; (b) intrinsic adenomyosis confirmed by preoperative MRI; (c) standardized JZ thickness assessment; and (d) treatment with FUAS. The exclusion criteria were: (a) patients with absence of preoperative magnetic resonance imaging (MRI) or incomplete JZ, DMI measurement; (b) concurrent uterine fibroids, endometriosis, or pelvic malignancy; (c) acute pelvic inflammatory disease; (d) inability to exclude malignancy; and (e) surgical or medical treatment for menorrhagia within 6 months prior to FUAS.
MRI Evaluation and Definitions
Pelvic MRI was performed using a 1.5T scanner with T2-weighted turbo spin-echo and diffusion-weighted sequences, following standardized protocols.6 Two radiologists, who were blinded to clinical outcomes, independently evaluated images, including MRI-based classification and evaluation of JZmax, DMI, and uterine and adenomyotic lesion volumes.6 JZmax was defined as the maximal thickness of the junctional zone.10 DMI was measured as the maximal distance from the endometrial–myometrial interface to the deepest extent of the adenomyotic lesion.13 Uterine and adenomyotic lesion volumes were calculated using the prolate ellipsoid formula: 0.52 × length × anteroposterior diameter × transverse diameter.16 In addition, an internal subtype of adenomyosis was defined as the basal endometrium invaginating into the myometrium with no involvement of the outer myometrial layer.17
FUAS Procedure, Follow-Up, and Outcome Definition
FUAS was performed using the focused ultrasound tumor therapeutic system (Model-JC200, Chongqing Haifu Technology Co., Ltd.) following standard protocols.18,19
Symptom recurrence was defined as the return of menorrhagia or dysmenorrhea after at least 3 months of symptom relief following FUAS.7 Patients were followed up via clinic visits or telephone interviews. The median follow-up period was 25 months (interquartile range (IQR): 15–46.5).
Statistical Analysis
Continuous variables were expressed as mean ± SD and compared through Student’s t-test. Categorical variables were compared by the chi-square test. Logistic regression was employed to identify factors associated with recurrence. ROC curve analysis was performed to determine the optimal cutoffs for JZmax and DMI. The association between COJD and recurrence-free survival was assessed using Kaplan–Meier curves (K-M) and multivariate Cox regression. All tests were two-sided, with P < 0.05 representing statistical significance. Analyses were performed using SPSS 22.0 and MedCalc 15.2.1.
Results
Patient Characteristics
Among the 326 patients, 58 (17.8%) experienced symptom recurrence. Compared with the non-recurrence group, JZmax (38.1 ± 13.0 mm vs 33.5 ± 10.8 mm, P < 0.05) and DMI apparently increased in the recurrence group, shown in Table 1.
|
Table 1 Clinicopathological Features |
COJD Scoring System
Based on receiver operating characteristic (ROC)-derived cutoffs, a COJD was constructed as follows in Table 2:
- COJD = 0: JZmax ≤ 23.1 mm and DMI ≤ 51.4 mm
- COJD = 1: JZmax > 23.1 mm or DMI > 51.4 mm
- COJD = 2: JZmax > 23.1 mm and DMI > 51.4 mm
|
Table 2 Prediction Scores of JZmax, DMI, and COJD of Symptom Recurrence in Adenomyosis |
COJD and Recurrence Risk
The distribution of COJD scores was presented as follows: COJD = 0 in 55 patients (16.9%), COJD = 1 in 189 patients (58.0%), and COJD = 2 in 82 patients (25.1%). Multivariate Cox regression analysis identified COJD as a significant independent predictor of recurrence (hazard ratio (HR) = 6.004, 95% confidence interval (CI): 1.125–32.054, P = 0.036) (Table 3).
|
Table 3 Multivariate Cox Regression Analysis of Factors for Symptom Recurrence of Adenomyosis |
ROC Analysis and Cutoff Determination
ROC curve analysis for JZmax yielded an optimal cutoff of 23.1 mm for symptom recurrence (sensitivity 98.3%, specificity 19.8%, area under the curve (AUC) = 0.612, P = 0.006). In terms of DMI, the optimal cutoff was 51.4 mm (AUC = 0.589, sensitivity 55.2%, specificity 62.7%, shown in Table S1 Figure 1).
Kaplan–Meier analysis exhibited a significant gradient in median recurrence time across COJD groups: 1) COJD = 0: 53.0 months; 2) COJD = 1: 45.8 months; 3) COJD = 2: 38.7 months;Log-rank P = 0.046 (Figure 2).
Discussion
This study indicated that the combination of JZmax with DMI—quantified as the COJD score—was a significant independent predictor of symptom recurrence after FUAS for intrinsic adenomyosis. Patients with a COJD score of 2 (both JZmax > 23.1 mm and DMI > 51.4 mm) suggested the shortest median time to recurrence (38.7 months), which was shown to be significantly shorter than that observed in patients with lower scores. These findings suggested that the COJD score may serve as a clinically useful tool for postoperative risk stratification. Compared to previous studies that primarily focused on individual parameters, our study introduces a novel, integrated scoring system that provides superior prognostic accuracy by combining functional and anatomical disease assessments.
The function of COJD in prognosis prediction may be ascribed to the fact that it integrates JZmax and DMI. In this work, patients developing relapsed symptoms showed markedly increased preoperative JZmax and DMI relative to those not developing recurrence, indicating that these two parameters indicate the associated disease severity. Notably, JZ thickening suggests tissue injury and repair (TIAR), chronic inflammation, and estrogen-driven hyperperistalsis, and these jointly establish a microenvironment good for ectopic endometrial survival and persistent disease.20–22 Furthermore, DMI suggests the myometrium’s anatomical involvement level as well as residual disease burden post-ablation.13 JZmax can reflect dysfunction at the endometrial–myometrial interface, and DMI can quantify adenomyosis invasiveness.15 Consequently, integrating these two parameters helps comprehensively assess their disease severity from the function and anatomy perspectives.14
Apparently, COJD performed well relative to single parameter, as revealed by multivariate Cox regression, and the HR was 6.004 (P = 0.036). Such a result suggests that the composite score is superior in prognosis modeling. Furthermore, the progressively increased recurrence risk due to growing COJD score, which were 53.0 and 38.7 months in the low- and high-risk groups separately, suggests that it may be used to guide follow-up intensity and inform decision-making concerning adjunctive treatment in high-risk patients.
In FUAS, such mechanistic knowledge assists in elucidating the relationship between higher preoperative JZmax and DMI and poor prognosis. FUAS can relieve symptom by thermally ablating ectopic endometrial tissue in adenomyosis, thus decreasing disease burden while mitigating relevant symptoms.6 Nonetheless, FUAS mainly targets the predominant lesion seen on imaging but can not totally remove microscopic ectopic foci, especially those situated deep in the myometrium or within the dysfunctional JZ microenvironment.
Although the predominant lesion is successfully ablated, the residual JZ shows a continuous dysfunctional state, characterized by dysregulated contractility, persistent angiogenesis, and chronic inflammation, which probably promotes microscopic disease regrowth, finally giving rise to symptom recurrence. Besides, the JZ thickening-related aberrant uterine peristalsis perpetuates mechanical irritation as well as tissue microtrauma, which activates the tissue injury and repair (TIAR) cycle and creates a pro-inflammatory environment good for the proliferation and survival of ectopic endometrial cells.13,23 Simultaneously, the angiogenic microenvironment enhanced by vascular endothelial growth factor (VEGF) upregulation contributes to recurrent or residual lesion revascularization, thus maintaining disease activity.24
DMI, which represents the myometrial infiltration depth, adds a new dimension to the pathophysiological condition. An increased invasion depth suggests the further extension of adenomyotic lesions from the endometrial–myometrial interface to the myometrium, which adds to the technical challenge in complete ablation.14 Lesions situated deeper are probably more proximal to key structures like uterine vasculature and serosa, which may limit the safety margin for delivering thermal energy in FUAS and increase the risk of residual viable tissue following treatment. In addition, extended myometrial involvement indicates an aggressive disease phenotype and an increased risk of regrowth.
For patients with a COJD score of 2, who were at the highest risk of early recurrence, alternative conservative techniques could be considered. Although FUAS yielded favorable outcomes for a large number of patients, the elevated recurrence risk observed in this specific subgroup indicated that hysterectomy or more aggressive combined medical and surgical approaches offered superior long-term symptom control. In contrast, for patients with COJD scores ranging from 0 to 1, FUAS demonstrated distinct advantages over alternative treatment modalities. Such benefits included lower complication rates, shorter recovery periods, and potentially reduced overall healthcare costs, which stemmed from its non-invasive properties and outpatient application setting. These inherent advantages rendered FUAS a particularly optimal first-line conservative treatment choice for patients with a low recurrence risk.
Taken together, such parameters obtain additional knowledge regarding disease chronicity and recurrence risk. To be specific, JZmax indicates dysregulation of function and microenvironment at the endometrial–myometrial interface, marking the “soil” condition fostering disease persistence, whereas DMI contributes to quantifying the anatomical invasion degree, which is the “seed” burden determining baseline disease volume as well as technical resectability. Consequently, integrating these two parameters in the COJD score can holistically assess the terrain for adenomyosis development and the entrenching depth inside the myometrium. Such dual perspective interprets the superior performance of their combination to a single parameter in predicting recurrence following FUAS, and highlights the importance of preoperative COJD evaluation in the identification of patients probably benefiting from close monitoring and adjunctive treatment post-ablation.
Based on these findings, we propose a management algorithm that stratifies patients by COJD score to guide clinical decision-making (Figure 3). For patients with COJD 0, routine FUAS followed by standard follow-up is recommended. For COJD 1, closer surveillance with imaging and symptom assessment at 6-month intervals is advised. For COJD 2, given the high recurrence risk, a multidisciplinary discussion should be considered to evaluate the potential benefits of adjunctive medical therapy or alternative surgical interventions.
Certain limitations should be noted in the present work. Firstly, considering the retrospective design, it is impossible to establish causal inferences concerning the relation of COJD with symptom recurrence, despite the potent relation observed. Secondly, patients with insufficient follow-up data were excluded, probably introducing selection bias, although great efforts were made to ensure sufficient data acquisition. Thirdly, symptom recurrence was self-reported by patients with the binary (yes/no) classification but not the well-established graded scale like the Numerical Rating Scale, probably affecting the symptom severity assessment accuracy. Fourthly, our single-center nature limits the result’s generalizability. Multicenter prospective studies that incorporate standard symptom metrics and verified outcome measures should be conducted for validating the COJD scoring system and refining risk prediction models.
Conclusions
To conclude, the COJD score, integrating JZmax and DMI, independently predicted symptom recurrence post-FUAS for adenomyosis. Typically, a score of 2 may identify patients with the greatest risk of early recurrence, which could instruct individualized postoperative monitoring and management.
Declaration of Generative AI and AI-Assisted Technologies in the Writing Process
During the preparation of this manuscript, the authors utilized ChatGPT‑4o, used for language polishing only. The authors carefully reviewed and edited all content generated by this tool and assume full responsibility for the final published work.
Abbreviations
MRI, Magnetic resonance imaging; FUAS, high-intensity focused ultrasound ablation; JZmax, junctional zone maximum; DMI, depth of myometrial invasion; COJD, combined with JZmax and DMI; ROC, receiver operating characteristic; IQR, interquartile range; M, Kaplan-Meier; AUC, area under the curve; TIAR, tissue injury and repair; VEGF, vascular endothelial growth factor.
Data Sharing Statement
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. With regard to the publication and utilization of datasets, all contributing authors to this article have executed consent declarations.
Ethics Statement
This retrospective cohort study was conducted in accordance with the Declaration of Helsinki and received ethical approval from the Institutional Review Board of the Affiliated Nanchong Central Hospital, North Sichuan Medical College (Approval No. 2021/104). All procedures performed in studies involving human participants were in accordance with the 1963 Helsinki Declaration. Informed consent was waived due to the anonymized nature of the data.
Author Contributions
All authors made a significant contribution to the work reported, whether that was in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.
Funding
This work was supported by the National Key R&D Plan for Intergovernmental Cooperation, the Ministry of Science and Technology of China (Grant No. 2022YFE0133100), and the Foundation of the State Key Laboratory of Ultrasound in Medicine and Engineering (Grant No. 2024KFKT016), Department of Science and Technology of Sichuan (Grant No. 2026SC0016235), and Municipal Science and Technology Bureau Project of Nanchong (Grant No. 25YYJCYJ007).
Disclosure
The authors report no conflicts of interest in this work.
References
1. Santulli P, Vannuccini S, Bourdon M, et al. Adenomyosis: the missed disease. Reprod Biomed Online. 2025;50(4):104837. doi:10.1016/j.rbmo.2025.104837
2. Tang Y, Wen MB, Xiang RM, et al. Serum CA125 as a biomarker for dysmenorrhea in adenomyosis. Int J Gynaecol Obstet. 2023;163(1):131–10. doi:10.1002/ijgo.14832
3. Shats M, Zajicek M, Siedhoff MT, et al. Updates on adenomyosis and fertility. Curr Opin Obstet Gynecol. 2025;37(4):198–206. doi:10.1097/gco.0000000000001039
4. Dason ES, Maxim M, Sanders A, et al. Guideline No. 437: diagnosis and management of adenomyosis. J Obstet Gynaecol Can. 2023;45(6):417–29.e1. doi:10.1016/j.jogc.2023.04.008
5. Kim EJ, Shim YS, Sung HK, et al. The efficacy and safety herbal medicine for symptom management after HIFU treatment in adenomyosis: a systematic review and meta-analysis. Pharmaceuticals. 2025;18(6). doi:10.3390/ph18060843
6. Tang Y, Hu WH, Wang H, et al. Magnetic resonance imaging-based classification systems for informing better outcomes of adenomyosis after ultrasound-guided high-intensity focused ultrasound ablating surgery. J Magn Reson Imaging. 2024;59(5):1787–1797. doi:10.1002/jmri.28943
7. Tang Y, Ming-Tao Y, Xiang RM, et al. Preoperative CA125 as a risk factor for symptom recurrence of adenomyosis after ultrasound-guided high-intensity focused ultrasound ablation surgery. Int J Hyperthermia. 2022;39(1):1164–1169. doi:10.1080/02656736.2022.2107716
8. Liu XF, Huang LH, Zhang C, et al. A comparison of the cost-utility of ultrasound-guided high-intensity focused ultrasound and hysterectomy for adenomyosis: a retrospective study. Bjog. 2017;124(Suppl 3):40–45. doi:10.1111/1471-0528.14746
9. Berbecaru EIA, Zorilă GL, Istrate-Ofiţeru AM, et al. Adenomyosis-modern techniques for ultrasound and histo-pathological diagnosis of the endo-myometrial junction zone changes. J Clin Med. 2025;14(24):8744. doi:10.3390/jcm14248744
10. Turtóczki K, Cho H, Dastaran S, et al. Evaluation of junctional zone differential and ratio as possible markers of clinical efficacy in uterine artery embolisation of adenomyosis. CVIR Endovasc. 2024;7(1):55. doi:10.1186/s42155-024-00468-0
11. Sasamoto N, Babic A, Rosner BA, et al. Predicting circulating CA125 levels among healthy premenopausal women. Cancer Epidemiol Biomarkers Prev. 2019;28(6):1076–1085. doi:10.1158/1055-9965.Epi-18-1120
12. Petrila O, Stefan AE, Gafitanu D, et al. The applicability of artificial intelligence in predicting the depth of myometrial invasion on MRI studies-a systematic review. Diagnostics. 2023;13(15):2592. doi:10.3390/diagnostics13152592
13. Liyanage A, Cardoza S, Kasabia D, et al. Accuracy of MRI in predicting deep myometrial invasion in endometrial cancer and the influence of leiomyoma, adenomyosis and the microcystic elongated and fragmented tumour pattern. J Med Imaging Radiat Oncol. 2024;68(3):235–242. doi:10.1111/1754-9485.13622
14. Dinoi G, Garzon S, Weaver A, et al. How deep is too deep? Assessing myometrial invasion as a predictor of distant recurrence in stage I endometrioid endometrial cancer. Int J Gynecol Cancer. 2024;34(9):1389–1398. doi:10.1136/ijgc-2023-005217
15. Ebrahim NAA, Eissa TS, Hussein MA, et al. Tight junction disruption via claudin-6 overexpression promotes invasion and recurrence in high-grade endometrial tumors. World J Clin Oncol. 2025;16(11):110257. doi:10.5306/wjco.v16.i11.110257
16. Tang Y, Jiang ZJ, Wen MB, et al. Magnetic resonance imaging-based classifications for symptom of adenomyosis. Gynecol Obstet Invest. 2024;89(5):402–412. doi:10.1159/000535802
17. Kishi Y, Suginami H, Kuramori R, et al. Four subtypes of adenomyosis assessed by magnetic resonance imaging and their specification. Am J Obstet Gynecol. 2012;207(2):114.e1–7. doi:10.1016/j.ajog.2012.06.027
18. Li X, Zhu X, He S, et al. High-intensity focused ultrasound in the management of adenomyosis: long-term results from a single center. Int J Hyperthermia. 2021;38(1):241–247. doi:10.1080/02656736.2021.1886347
19. Hu Y, Song X, Xu L, et al. High-intensity focused ultrasound is a better choice for women with fertility desire: a systematic review and meta-analysis of the comparison between high-intensity focused ultrasound and laparoscopic treatment of uterine fibroids. Gynecol Minim Invasive Ther. 2024;13(2):79–89. doi:10.4103/gmit.gmit_23_23
20. Tanos V, Lingwood L, Balami S. The importance of the junctional zone of the endometrium in human reproduction. Hum Fertil. 2022;25(1):4–12. doi:10.1080/14647273.2020.1720316
21. Atabekoğlu CS, Şükür YE, Kalafat E, et al. The association between adenomyosis and recurrent miscarriage. Eur J Obstet Gynecol Reprod Biol. 2020;250:107–111. doi:10.1016/j.ejogrb.2020.05.006
22. Gillet E, Tanos P, Van Kerrebroeck H, et al. Intrauterine application of Budesonide-hyaluronic acid gel in patients with recurrent implantation failure and total loss of junctional zone differentiation on magnetic resonance imaging. Facts Views Vis Obgyn. 2025;17(3):237–244. doi:10.52054/fvvo.2025.89
23. Wang S, Li B, Shen X, et al. The cannabinoid receptor CB1 affects the proliferation and apoptosis of adenomyotic human uterine smooth muscle cells of the junctional zone: a mechanism study. Reprod Biol Endocrinol. 2021;19(1):16. doi:10.1186/s12958-020-00690-0
24. Lupicka M, Zadroga A, Szczepańska A, et al. Effect of ovarian steroids on vascular endothelial growth factor a expression in bovine uterine endothelial cells during adenomyosis. BMC Vet Res. 2019;15(1):473. doi:10.1186/s12917-019-2222-0
© 2026 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms and incorporate the Creative Commons Attribution - Non Commercial (unported, 4.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.